218594-88-8 Usage
General Description
(S)-3-Ethylmorpholine hydrochloride is a chemical compound that is typically used as a reagent in organic synthesis and as a pharmaceutical intermediate. It is a derivative of morpholine and is commonly utilized in the production of various drugs and pharmaceuticals. (S)-3-Ethylmorpholine hydrochloride is known for its ability to serve as a chiral ligand and is often used in asymmetric synthesis. Additionally, (S)-3-Ethylmorpholine hydrochloride has been found to have potential applications in the development of new materials and as a building block for the creation of complex organic molecules. Overall, this chemical exhibits versatile properties that make it valuable in the field of organic chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 218594-88-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,5,9 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 218594-88:
(8*2)+(7*1)+(6*8)+(5*5)+(4*9)+(3*4)+(2*8)+(1*8)=168
168 % 10 = 8
So 218594-88-8 is a valid CAS Registry Number.
218594-88-8Relevant articles and documents
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease
Fukunaga, Kenji,Sakai, Daiki,Watanabe, Kazutoshi,Nakayama, Kazuki,Kohara, Toshiyuki,Tanaka, Hiroshi,Sunada, Shinji,Nabeno, Mika,Okamoto, Masako,Saito, Ken-Ichi,Eguchi, Jun-Ichi,Mori, Akiko,Tanaka, Shinji,Inazawa, Keiko,Horikawa, Takashi
, p. 1086 - 1091 (2015/02/19)
We herein describe the results of further evolution of GSK-3β inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3β inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models.
